Search
Now showing items 1-10 of 498
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
An evaluation of contouring and planning methods to expand the role of SBRT with CyberKnife in the treatment of localised prostate and renal cancers
(Institute of Cancer Research (University Of London), 2022-05-31)
Technological advancement has led to the substantial evolution of stereotactic body radiotherapy (SBRT). The CyberKnife SBRT platform achieves a high degree of precision through robotic delivery of multiple non-coplanar ...
Identification of novel targets for the treatment of endocrine-resistant breast cancer
(Institute of Cancer Research (University Of London), 2022-05-31)
While endocrine therapy is an effective, well-tolerated treatment for oestrogen receptor positive (ER-positive) breast cancer, a large proportion of initial responders will develop hormone therapy resistance, and relapse. ...
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
(Institute of Cancer Research (University Of London), 2022-04-30)
The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ...
Targeting the tumour microenvironment with endosialin-directed CAR T-cells
(Institute of Cancer Research (University Of London), 2022-05-31)
Advances in T-cell engineering have facilitated the generation of CAR T-cells that successfully deplete malignant cells of haematological cancers. However, attempts to target solid tumours with CAR T-cells have been hindered ...
Local control and toxicity after hypofractionated accelerated palliative RT in breast cancer
(ELSEVIER IRELAND LTD, 2022-05-01)
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
(AMER MEDICAL ASSOC, 2022-05-02)
Importance: There is a need to tailor treatments to patients who are most likely to derive the greatest benefit from them to improve patient outcomes and enhance cost-effectiveness of cancer therapies. Objective: To compare ...
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
(Elsevier BV, 2022-08-11)
PURPOSE: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term ...
Selective autophagy controls innate immune response through a TAK1/TAB2/SH3PX1 axis.
(CELL PRESS, 2022-01-25)
Selective autophagy is a catabolic route that turns over specific cellular material for degradation by lysosomes, and whose role in the regulation of innate immunity is largely unexplored. Here, we show that the apical ...
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
(ELSEVIER SCI LTD, 2022-07-01)
BACKGROUND: Statins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties. METHODS: Patient data ...